Cantab deal with Glaxo on shaky ground

Cantab (LSE:CTB; CNTBY) said that its deal with Glaxo (GLX; LSE:GLXO) to develop CTB's DISC-HSV herpes vaccine, in Phase II, may be in jeopardy. The deal, struck in 1997, may be terminated following G...